VersaCap® Technology Aids Critical Vaccine Trial, NBC Nightly News

Press Release from Foxx Life Sciences

Moderna continues to run the COVID-19 vaccine trials. They aim to enroll 30,000 adults in the clinical trial, which is designed to test whether the vaccine works to prevent COVID-19. The trial will also look at the vaccine's safety.

Participants will either receive the vaccine or a placebo. They will be tracked for two years to see whether they get COVID-19 or have any adverse reactions to the vaccine.

In an editorial published alongside the study, Dr. Penny Heaton, the chief executive officer of the Bill and Melinda Gates Research Institute in Cambridge, Massachusetts, wrote that the data are "promising."
Foxx Life Sciences' VersaCap technology is seen used in a lab in the segment above. VersaCap eliminates the risk of pouring high-value substances with top quality Caps and Adapters. The caps are compatible with a wide range of adapter inserts that feature a leak-proof design. These caps and adapters are ideally used for liquid handling and transfer applications in industries like pharmaceuticals and biotechnology. All caps are Class VI, BSE Free, and have passed USP 665 L&E testing. Available in 38-430, GL45, 53B, 83B, and 120mm sizes!
Companies Mentioned in this Press Release:
Business Categories Mentioned in this Press Release: